Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities

Current Pharmaceutical Design

Volumn 14, Issue 28, 2008, Pages 2983-2998

  Mishani, Eyal ^a   Abourbeh, Galith ^a   Eiblmaier, Martin ^b   Anderson, Carolyn J ^b,c  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WASHINGTON UNIVERSITY   (United States)

Author keywords

Cancer; Cetuximab; EGFR; Gefitinib; Imaging; PET; Tyrosine kinase

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; BEVACIZUMAB; CANERTINIB; CETUXIMAB; COMPLEMENT; COPPER 64; DEFEROXAMINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ERLOTINIB; GEFITINIB; IMATINIB; INDIUM 111; IODINE 125; LAPATINIB; LUTETIUM 177; MATUZUMAB; MONOCLONAL ANTIBODY; PANITUMUMAB; PELITINIB; PENTETIC ACID; PROTEIN TYROSINE KINASE; SEMAXANIB; SUNITINIB; TRASTUZUMAB; UNINDEXED DRUG; VATALANIB; YTTRIUM; ZIRCONIUM; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; PROTEIN KINASE INHIBITOR; RADIOPHARMACEUTICAL AGENT;

ANGIOGENESIS; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; APOPTOSIS; BREAST CANCER; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; COMPLEMENT DEPENDENT CYTOTOXICITY; COMPUTER ASSISTED TOMOGRAPHY; DRUG APPROVAL; DRUG BINDING; DRUG EFFICACY; DRUG STRUCTURE; DRUG TARGETING; EOSINOPHILIC LEUKEMIA; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HEAD AND NECK CANCER; HUMAN; INHIBITION KINETICS; KIDNEY CANCER; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MOLECULAR IMAGING; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MEDICINE; OVARY CANCER; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RECEPTOR OCCUPANCY; REVIEW; SIGNAL TRANSDUCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT OUTCOME; ANIMAL; DRUG DELIVERY SYSTEM; DRUG EFFECT; GENE EXPRESSION REGULATION; METABOLISM; METHODOLOGY; NEOPLASM; SCINTISCANNING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN KINASE INHIBITORS; RADIOPHARMACEUTICALS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 58149392589     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208786404326     Document Type: Review

References (119)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics. CA Cancer J Clin 2002; 55: 75-108.
2. Ciardiello F. Epidermal growth factor receptor tyrosine kinase inhibitors as agents. Drugs 2000; 60: 25-32.
3. Renhowe PA. Growth factor receptor kinases in cancer. Ann Rep Med Chem 2001; 36: 109-18.
4. Rowinsky EK. The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agents. Drugs 2000; 1: 1-14.
5. Hubbard SR, Miller WT. Receptor tyrosine kinases: Mechanisms of activation and signaling. Curr Opin Cell Biol 2007; 19: 117-23.
6. Laskin JJ, Sandler AB. Epidermal growth factor receptor: A promising target in solid tumours. Cancer Treat Rev 2004; 30: 1-17.
7. Yarden Y. The EGFR family and its ligands in human cancer. Signaling mechanisms and therapeutic opportunities. Eur J Cancer 2001; 37(Suppl 4): S3-8.
8. Grünwald V, Hidalgo M. The epidermal growth factor receptor: A new target for anticancer therapy. Curr Probl Cancer 2002; 26: 114-64.
9. Kralovics RF, Passamonti AS, Buser SS, Teo R, Tiedt JR, Passweg A, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-90.
10. Levitzki A. EGF receptor as a therapeutic target. Lung Cancer 2003; 41: S9-14.
11. Ritter CA, Arteaga CL. The epidermal growth factor receptor-tyrosine kinase: A promising therapeutic target in solid tumors. Semin Oncol 2003; 30: 3-11.
12. Stern DF. Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases. Breast Cancer Res 2000; 2: 176-83.
13. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, et al. A census of human cancer genes. Nat Rev Cancer 2004; 4: 177-83.
14. Blume-Jensen P, Hunter T. Oncogenic kinase signaling. Nature 2001; 411: 355-65.
15. Levitzki A, Mishani E. Tyrphostins and other tyrosine kinase inhibitors. Ann Rev Biochem 2006; 75: 93-109.
16. Baselga J. Targeting tyrosine kinases in cancer: The second wave. Science 2006; 312: 1175-8.
17. Fry DW. Protein tyrosine kinases as therapeutic targets in cancer chemotherapy and recent advances in the development of new inhibitors. Exp Opin Invest Drugs 1994; 3: 577-95.
18. Traxler P, Bold G, Buchdunger E, Caravatti G, Furet P, Manley P, et al. Tyrosine kinase inhibitors: From rational design to clinical trials. Med Res Dev 2001; 21: 499-512.
19. Hopfner M, Schuppan D, Scherubl H. Growth factor receptors and related signaling pathways as targets for novel treatment strategies of hepatocellular cancer. World J Gastroenterol 2008; 14: 1-14.
20. Rodriguez J, Zarate R, Bandres E, Viudez A, Chopitea A, Garcia-Foncillas J, et al. Combining chemotherapy and targeted therapies in metastatic colorectal cancer. World J Gastroenterol 2007; 13: 5867-76
21. Giamas G, Stebbing J, Vorgias CE, Knippschild U. Protein kinases as targets for cancer treatment. Pharmacogenomics 2007; 8: 1005-16.
22. Sergina NV, Moasser MM. The HER family and cancer: Emerging molecular mechanisms and therapeutic targets. Trends Mol Med 2007; 13: 527-34
23. Levitzki A. Protein kinase inhibitors as a therapeutic modality. Acc Chem Res 2003; 36: 462-9.
24. Levitzki A. Tyrphostins: Tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction. FASEB J 1992; 6: 3275-82.
25. Levitzki A, Gazit A. Tyrosine kinase inhibition: An approach to drug development. Science 1995; 267: 1782-8.
26. Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 2006; 6: 714-27.
27. Bennasroune A, Gardin A, Aunis D, Cremel G, Hubert P. Tyrosine kinase receptors as attractive targets for cancer therapy. Crit Rev Oncol Hematol 2004; 50: 23-8.
28. Mass RD. The HER receptor family: A rich target for therapeutic development. Int J Radiat Oncol Biol Phys 2004; 58: 932-40.
29. Mass RD, Press MF, Anderson S, Cobleigh MA, Vogel CL, Dybdal N, et al. Evaluation of clinical outcomes according to HER2 detecton by fluorescence in situ hybridizationo in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer 2005; 6: 240-6.
30. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45.
31. Bernier J. Cetuximab in the treatment of head and neck cancer. Expert Rev Anticancer Ther 2006; 6: 1539-52.
32. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23: 1803-10.
33. Hoy SM, Wagstaff AJ. Panitumumab: In the treatment of metastatic colorectal cancer. Drugs 2006; 66: 2005-14.
34. Berlin J, Posey J, Tchekmedyian S, Hu E, Chan D, Malik I, et al. Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer. Clin Colorectal Cancer 2007; 6: 427-32.
35. Cohenuram M, Saif MW. Panitumumab the first fully human monoclonal antibody: From the bench to the clinic. Anticancer Drugs 2007; 18: 7-15.
36. Labianca R, La Verde N, Garassino MC. Development and clinical indications of cetuximab. Int J Biol Markers 2007; 22(1 Suppl 4): S40-6.
37. Bajetta E, Procopio G, Verzoni E, Catena L, De Dosso S, Platania M, et al. Renal cell cancer and sorafenib: Skin toxicity and treatment outcome. Tumori 2007; 93: 201-3.
38. Graziani Y, Chayoth R, Karny N, Feldman B, Levy J. Regulation of protein kinases activity by quercetin in Ehrlich ascites tumor cells. Biochim Biophys Acta 1982; 714: 415-21.
39. Graziani Y, Erikson E, Erikson RL. The effect of quercetin on the phosphorylation activity of the Rous sarcoma virus transforming gene product in vitro and in vivo. Eur J Biochem 1983; 135: 583-9.
40. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 1987; 262: 5592-5.
41. Onoda T, Iinuma H, Sasaki Y, Hamada M, Isshiki K, Naganawa H, et al. Isolation of a novel tyrosine kinase inhibitor, lavendustin A, from Streptomyces griseolavendus. J Nat Prod 1989; 52: 1252-7.
42. Umezawa H, Imoto M, Sawa T, Isshiki K, Matsuda N, Uchida T, et al. Studies on a new epidermal growth factor-receptor kinase inhibitor, erbstatin, produced by MH435-hF3. J Antibiot (Tokyo) 1986; 39: 170-3.
43. Imoto M, Umezawa K, Sawa T, Takeuchi T, Umezawa H. In situ inhibition of tyrosine protein kinase by erbstatin. Biochem Int 1987; 15: 989-95.
44. Yaish P, Gazit A, Gilon C, Levitzki A. Blocking of EGF-dependent cell proliferation of EGF receptor kinase inhibitors. Science 1988; 242: 933-35.
45. Gazit A, Yaish P, Gilon C, Levitzki A. Tyrphostins I: Synthesis and biological activity of protein tyrosine kinase inhibitors. J Med Chem 1989; 32: 2344-52.
46. Shiraishi T, Owada MK, Tatsuka M, Yamashita T, Watanabe K, Kakunaga T. Specific inhibitors of tyrosine-specific protein kinases: Properties of 4-hydroxycinnamamide derivatives in vitro. Cancer Res 1989; 49: 2374-8.
47. Shiraishi T, Owada MK, Tatsuka M, Fuse Y, Watanabe K, Kakunaga T. A tyrosine-specific protein kinase inhibitor, alphacyano-3-ethoxy-4-hydroxy-5-phenylthiomethylcinnamamide, blocks the phosphorylation of tyrosine kinase substrate in intact cells. Jpn J Cancer Res 1990 ; 81: 645-52.
48. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561-6.
49. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-7.
50. Blanke CD, Corless CL. State-of-the art therapy for gastrointestinal stromal tumors. Cancer Invest 2005; 23: 274-80.
51. Liu Y, Poon RT, Li Q, Kok TW, Lau C, Fan ST. Both antiangiogeneis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res 2005; 65: 3691-9.
52. Steeghs N, Nortier JW, Gelderblom H. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: An update of recent developments. Ann Surg Oncol 2007; 14: 942-63.
53. Wiedmann N, Feisthammal J, Bluthner T, Tannapfel A, Kamenz T, Kluge A, et al. Novel targeted approaches to treatment biliary tract cancer: The dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib. Anticancer Drugs 2006; 17: 783-95.
54. De Mulder PH, Roigas J, Gillessen S. A phase II study of sunitinib administered in a continuous daily regimen in patients with cytokine-refractory metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 2006; 24: 223s.
55. Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999; 59: 99-106.
56. Rosen P, Amado R, Hecht J. A phase I/II study of SU5416 in combination with 5-FU/leucovorin in patients with metastatic colorectal cancer. Proc Ac Soc Clin Oncol 2000; 18: 5a.
57. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000; 60: 2178-89.
58. Sridhar SS, Shepherd FA. Targeting angiogenesis: A review of angiogenesis inhibitors in the treatment of lung cancer. Lung Cancer 2003; 42: S81-91.
59. Jung YD, Mansfield PF, Akagi M, Takeda A, Liu W, Bucana CD, et al. Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of a gastric cancer in a nude mouse model. Eur J Cancer 2002; 38: 1133-40.
60. Baselga J, Averbuch SD. ZD1839 ('Iressa'), as an Anticancer Agent. Drugs 2000; S1: 33-40.
61. Akita RW, Sliwkowski MX. Preclinical studies with Erlotinib (Tarceva). Semin Oncol 2003; S7: 15-24.
62. Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005; 23: 6829-37.
63. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500.
64. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-39.
65. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, et al. Erlotinib in lung cancer - Molecular and clinical predictors of outcome. N Engl J Med 2005; 352: 133-44.
66. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101: 13306-11.
67. Riely GJ, Politi KA, Miller VA, Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 2006; 12: 7232-41.
68. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2: E73.
69. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, et al. EGFR Mutation and resistance of non-small-cell lung cancer to Gefitinib. N Engl J Med 2005; 352: 786-92.
70. Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 2005; 102: 7665-70.
71. Yoshimura N, Kudoh S, Kimura T, Mitsuoka S, Matsuura K, Hirata K, et al. EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib. Lung Cancer 2006; 51: 363-8.
72. Cohen MH, Williams GA, Sridhara R, Chen G, McGuinn WD Jr, Morse D, et al. United states food and drug administration drug approval summary: gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004; 10: 1212-8.
73. Maione P, Gridelli C, Troiani T, Ciardiello F. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC. Oncologist 2006; 11: 274-84.
74. Cai W, Niu G, Chen X. Multimodality imaging of the HER-kinase axis in cancer. Eur J Nucl Med Mol Imaging 2008; 35: 186-8.
75. Weiner RE, Thakur ML. Radiolabeled peptides in oncology: Role in diagnosis and treatment. BioDrugs 2005; 19: 145-63.
76. Dziadziuszko R, Hirsch FR, Varella-Garcia M, Bunn Jr PA. Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization. Why, when, and how? Clin Cancer Res 2006; 12: S4409-15.
77. Mishani E, Abourbeh G. Cancer molecular imaging: Radionuclide-based biomarkers of the Epidermal Growth Factor Receptor (EGFR). Curr Topics Med Chem 2007; 7: 1755-72.
78. Goldenberg A, Masui H, Divgi C, Kamrath H, Pentlow KS, Mendelsohn J. Imaging of human tumor xenografts with an indium-111-labeled anti-epidermal growth factor receptor monoconal antibody. J. Natl Cancer Inst 1989; 82: 1616-25.
79. Wen X, Wu Q, Ke S, Ellis L, Charnsangavej C, Delpassand AS, et al. Conjugation with 111In-DTPA-Poly(ethylene glycol) improves imaging of anti-EGF receptor antobody C225. J Nucl Med 2001; 42: 1530-7.
80. Fan Z, Masui H, Altas I, Mendelsohn J. Blockage of epidermal growth factor receptor function by bivalent and monovalent fragments of C225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1993; 53: 4322-8.
81. Perk LR, Visser GW, Vosjan MJ, Stigter-van Walsum M, Tijink B M, Leemans CR, et al. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. J Nucl Med 2005; 46: 1898-906.
82. Cai W, Chen K, He L, Cao Q, Koong A, Chen X. Quantitative PET of EGFR expression in xenograft-bearing mice using (64)Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging 2007; 34: 850-8.
83. 64Cu-DOTA-cetuximab, a PET imaging agent for epidermal growth factor receptor positive tumors. Cancer Biother Radiopharm 2008; (in press).
84. Nordberg E, Friedman M, Gostring L, Adams GP, Brismar H, Nilsson FY, et al. Cellular studies of binding, internalization and retention of a radiolabeled EGFR-binding affibody molecule. Nucl Med Biol 2007; 34: 609-18.
85. Friedman M, Nordberg E, Hoiden-Guthenberg I, Brismar H, Adams GP, Nilsson FY, et al. Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor. Protein Eng Des Sel 2007; 20: 189-99.
86. Nordberg E, Orlova A, Friedman M, Tolmachev V, Stahl S, Nilsson FY, et al. In vivo and in vitro uptake of 111In, delivered with the affibody molecule (ZEGFR: 955)2, in EGFR expressing tumour cells. Oncol Rep 2008; 19: 853-7.
87. Friedman M, Orlova A, Johansson E, Eriksson TL, Hoiden-Guthenberg I, Tolmachev V, et al. Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule. J Mol Biol 2008; 376: 1388-402.
88. Mulholland GK, Zheng Q-H, Winkle WL, Carlson KA. Synthesis and biodistribution of new C-11 and F-18 labeled epidermal growth factor receptor ligands. J Nucl Med 1997; 38: 141P.
89. 11C-labeled PD153035 in rats without and with neuroblastoma implants. Life Sci 1999; 65: 165-74.
90. Mulholland GK, Winkle W, Mock BH, Sledge J. Radioiodinated epidermal growth factor receptor ligands as tumor probels. Dramatic potentiation of binding to MDA-468 cancer cells in presence of EGF. J Nucl Med 1995; 36: 71P.
91. Mattner F. Radioiodinated epidermal growth factor receptor inhibitors for tumor imaging with SPECT. Quart J Nucl Med 2001; 45: S6.
92. Seimbille Y, Phelps ME, Czernin J, Silverman DHS. Fluorine-18 labeling of 6,7-disubstituted anilinoquinazoline derivatives for positron emission tomography (PET) imaging of tyrosine kinase receptors: synthesis of 18F-Iressa and related molecular probes. J Label Comp Radiopharm 2005; 48: 829-43.
93. Mishani E, Bonasera TA, Rozen Y, Ortu G, Gazit A, Levitzki A. Fluorinated EGFR-TK inhibitors-based tracers for PET. J Label Cpd Radiopharm 1999; 42: S27-9.
94. Bonasera TA, Ortu G, Rozen Y, Krais R, Freedman NM, Chisin R, et al. Potential (18)F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase. Nucl Med Biol 2001; 28: 359-74.
95. 68Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors. J Nucl Med 2005; 46: 1881-8.
96. Masui H, Castro L, Mendelsohn J. Consumption of EGF by A431 Cells: Evidence for receptor recycling. J Cell Biol 1993; 120: 85-93.
97. Yang XD, Jia XC, Corvalan JRF, Wang P, Davis CG. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001; 38: 17-23.
98. 11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase. Bioorg Med Chem 2006; 16: 4102-6.
99. DeJesus OT, Murali D, Flores LG, Converse AK, Dick DW, Oakes TR, et al. Synthesis of [F-18]-ZD1839 asa PET imaging agent for epidermal growth factor receptors. J Labelled Comp Radiopharm 2003; 46: S1.
100. 18F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors. Eur J Nucl Med Mol Imaging 2008; Epub ahead of print.
101. Mishani E, Ben-David I, Rozen Y, Ortu G, Leviztki A. Carbon -11 labeled irreversible inhibitor for mapping epidermal growth factor receptor tyrosine kinase (EGFR-TK). J Label Cpd Radiopharm 2001; 44: S99-101.
102. Ortu G, Ben-David I, Rozen Y, Freedman NM, Chisin R, Levitzki A, et al. Labeled EGFr-TK irreversible inhibitor (ML03). In vitro and in vivo properties, potential as PET biomarker for cancer and feasibility as anticancer drug. Int J Cancer 2002; 101: 360-70.
103. Ben-David I, Rozen Y, Ortu G, Mishani E. Radiosynthesis of ML03, a novel positron emission tomography biomarker for targeting epidermal growth factor receptor via the labeling synthon: [C-11]Acryloyl chloride. Appl Rad Isotop 2003; 58: 209-17.
104. Shaul M, Abourbeh G, Jacobson O, Rozen Y, Laky D, Levitzki A, et al. Novel iodine-124 labeled EGFR inhibitors as potential PET agents for molecular imaging in cancer. Bioorg Med Chem 2004; 12: 3421-9.
105. Mishani E, Abourbeh G, Rozen Y, Jacobson O, Lacy D, Ben David I, et al. Novel carbon-11 labeled 4-dimethylamino-but-2-enoic acid [4-(phenylamino)-quinazoline-6-yl]amides: Potential PET bioprobes for molecular imaging of EGFR-positive tumors. Nucl Med Biol 2004; 31: 469-76.
106. Mishani E, Abourbeh G, Jacobson O, Dissoki S, Ben Daniel R, Rozen Y, et al. High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors. J Med Chem 2005; 48: 5337-48.
107. Vasdev N, Dorff PN, Gibbs AR, Nandanan E, Reid LM, O'Neil JP, et al. Synthesis of 6-acrylamido-4-(2-[18F]fluoroanilino)quinazo-line: A prospective irreversible EGFR binding probe. J Labelled Comp Radiopharm 2005; 48: 109-15.
108. Dissoki S, Laky D, Mishani E. Fluorine-18 labeling of ML04 - presently the most promising irreversible inhibitor candidate for visualization of EGFR in cancer. J Labelled Comp Radiopharm 2006; 49: 533-43.
109. Abourbeh G, Dissoki S, Jacobson O, Litchi A, Ben Daniel R, Laki D, et al. Evaluation of radiolabeled ML04, a putative irreversible inhibitor of the epidermal growth factor receptor, as a bioprobe for pet imaging of EGFR overexpressing tumors. Nucl Med Bio 2007; 34: 55-70.
110. Pal A, Glekas A, Doubrovin M, Balatoni J, Beresten T, Maxwell D, et al. Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography. Mol Imaging Biol 2006; 8: 262-77.
111. 18F]-PEG group on tracer qualification of [4-(phenylamino)-quinazoline-6-yl]-amide moiety - an EGFR putative irreversible inhibitor. Appl Rad Isotp 2007; 65: 1140-51.
112. Waldherr C, Satyamurthy N, Toyokuni T, Wang S, Mellinghoff I, Tran C, et al. Evaluation of N-{4-[(3 '-[F-18]fluoroethylphenyl) amino]-6-quinazolinyl}acrylamide ([F-18]FEQA), a labeled tyrosine kinase inhibitor, for imaging epidermal growth factor receptor density. J Nucl Med 2003; 44: 372P.
113. Fry DW, Bridges AJ, Denny WA, Doherty A, Greis KD, Hicks JL, et al. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc Natl Acad Sci USA 1998; 95: 12022-7.
114. Smaill JB, Showalter HD, Zhou H, Bridges AJ, McNamara DJ, Fry DW, et al. Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor. J Med Chem 2001; 44: 429-40.
115. Tsou HR, Mamuya N, Johnson BD, Reich MF, Gruber BC, Ye F, et al. 6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity. J Med Chem 2001; 44: 2719-34.
116. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183-232.
117. Hamoudeh M, Kamleh MA, Diab R, Fessi H. Radionuclides delivery systems for nuclear imaging and radiotherapy of cancer. Adv Drug Deliv Rev 2008; 60(12): 1329-46.
118. Pastorekova S, Zatovicova M, Pastorek J. Cancer-associated carbonic anhydrases and their inhibition. Curr Pharm Des 2008; 14(7): 685-98
119. Puttini M, Redaelli S, Moretti L, Brussolo S, Gunby RH, Mologni L, et al. Characterization of compound 584, an Abl kinase inhibitor with lasting effects. Haematologica 2008; 93(5): 653-61.